Patents by Inventor Deqiang Niu

Deqiang Niu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MK2 inhibitors and uses thereof
    Patent number: 9790235
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 17, 2017
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170267685
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • Heteroaryl compounds and uses thereof
    Patent number: 9765038
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 19, 2017
    Assignee: Celgene CAR LLC
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Juswinder Singh
  • Ligand-Directed Covalent Modification of Protein
    Publication number: 20170218353
    Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20170210729
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 27, 2017
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • Heteroaryl compounds and uses thereof
    Patent number: 9695132
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: July 4, 2017
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • HCV protease inhibitors and uses thereof
    Patent number: 9694086
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 4, 2017
    Assignee: Celgene CAR LLC
    Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
  • Protein Kinase Conjugates and Inhibitors
    Publication number: 20170174691
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Application
    Filed: July 18, 2016
    Publication date: June 22, 2017
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • HCV protease inhibitors and uses thereof
    Patent number: 9676785
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: June 13, 2017
    Assignee: Celgene CAR LLC
    Inventors: Deqiang Niu, Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Lixin Qiao
  • Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
    Patent number: 9663524
    Abstract: The present invention provides compounds of formula I-h: useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 30, 2017
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20170137406
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 18, 2017
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • HCV PROTEASE INHIBITORS AND USES THEREOF
    Publication number: 20170137463
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 5, 2016
    Publication date: May 18, 2017
    Inventors: Deqiang Niu, Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Lixin Qiao
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20170114073
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 27, 2017
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170100397
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: April 13, 2017
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • ERK inhibitors and uses thereof
    Patent number: 9561228
    Abstract: Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 7, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20170027937
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: February 2, 2017
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • Protein kinase conjugates and inhibitors
    Patent number: 9556426
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 31, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Macrocylic oximyl hepatitis C protease inhibitors
    Patent number: 9526769
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: December 27, 2016
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Deqiang Niu, Guoyou Xu, Yat Sun Or, Zhe Wang
  • ERK inhibitors and uses thereof
    Patent number: 9504686
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 29, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF
    Publication number: 20160332994
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 29, 2016
    Publication date: November 17, 2016
    Inventors: Kwangho Lee, Deqiang Niu, Matthew Frank Baevsky